FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Tuesday

 

New jab that creates 'killer cells' could help fight against MS: VIDEO































The new jab might be the hope to those suffering from multiple sclerosis

A NEW drug that creates natural ‘killer cells’ in the body has been hailed as a great leap forward in the fight against multiple sclerosis.

The monthly jab works by rebalancing the immune system and increasing the number of the body’s own killer cells.

It is hoped the drug - daclizumab - will be available to patients within months.

Daclizumab has been licensed for use in the UK for patients with the relapsing form of the disease, the type that affects 80 percent of sufferers.

Approximately 100,000 people in the UK suffer with MS.

It causes inflammation, which damages the central nervous system, stopping the nerves from working properly.

Symptoms include loss of mobility, speech problems, spasms and difficulties with thinking and memory. It has very few treatment options and often patients live for many years with the debilitating symptoms.

In the DECIDE study, the largest clinical trial ever undertaken in MS, daclizumab was shown to reduce the frequency of attacks (or relapses), by 45 percent compared to interferon-beta-1a, the current standard therapy.

It slowed the progression of the disease by 76 percent when compared with placebo over the course of a year and by 27 percent compared to interferon beta-1a over two to three years.

It is also very effective at reducing the development of new brain lesions.

Professor Gavin Giovannoni, head of neurology at Barts and The London School of Medicine and Dentistry said: “The authorisation of daclizumab is step forward in the fight against MS.”

“The fact that it works in a different way to other therapies not only furthers our understanding of this complex disease but also gives patients and clinicians an additional treatment to consider which is vital because the course of the condition can be so different from patient to patient.”

Side effects include skin reactions and liver problems.

Professor Giovannoni said: “Daclizumab is thought to work by targeting the growth of activated T cells, which are known to damage myelin, or insulating, sheath that cover nerve fibres.

Additionally, it increases the number of so-called natural killer cells in the body, strengthening their natural ability to find and kill existing activated T cells.”

Nick Rijke of the MS Society, said: “We are delighted to see another treatment authorised for MS. We are now working with NICE to try to ensure that daclizumab is made available through the NHS.

“Dacluzimab has been shown to be an effective treatment for people with MS, reducing relapses and slowing disability progression.”

Last month, the University of Ottawa in Canada reported that patients given aggressive chemotherapy combined with a transplant of their own cells, were described as a close to being a cure for MS.

The chemotherapy destroyed the immune system instead of suppressing it as in standard treatment.

It was then “reset” using blood stem cells.

But of the 24 patients who were treated, one died as a consequence and it was said the study was too small to assess the true dangers of the therapy.

Story Source: The above story is based on materials provided by EXPRESS
Note: Materials may be edited for content and length

Labels:



Go to Newer News Go to Older News